The immunological impact of genetic drift in the B10.BR congenic inbred mouse strain

Journal of Immunology

Volumn 183, Issue 7, 2009, Pages 4261-4272

  Fanning, Stacey L ^a   Appel, Michael Y ^a   Berger, Stephanie A ^a   Korngold, Robert ^a   Friedman, Thea M ^a  

^a HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CONGENIC STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC DRIFT; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECTROSCOPY; ACUTE DISEASE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CBA MOUSE; CD8+ T LYMPHOCYTE; CROSS BREEDING; GENETICS; IMMUNOLOGY; METABOLISM; MORTALITY; SPECIES DIFFERENCE; TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSSES, GENETIC; GENETIC DRIFT; GRAFT VS HOST DISEASE; MALE; MICE; MICE, CONGENIC; MICE, INBRED C57BL; MICE, INBRED CBA; MINOR HISTOCOMPATIBILITY ANTIGENS; SPECIES SPECIFICITY;

EID: 70449723397     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900971     Document Type: Article

References (68)

1. Stevens, J. C., G. T. Banks, M. F. Festing, and E. M. Fisher. 2007. Quiet mutations in inbred strains of mice. Trends Mol. Med. 13: 512-519.
2. Bedell, M. A., D. A. Largaespada, N. A. Jenkins, and N. G. Copeland. 1997. Mouse models of human disease, II: Recent progress and future directions. Genes Dev. 11: 11-43.
3. Hann, B., and A. Balmain. 2001. Building "validated" mouse models of human cancer. Curr. Opin. Cell Biol. 13: 778-784.
4. Allred, D. C., and D. Medina. 2008. The relevance of mouse models to understanding the development and progression of human breast cancer. J. Mammary Gland Biol. Neoplasia 13: 279-288.
5. Hanahan, D., E. F. Wagner, and R. D. Palmiter. 2007. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 21: 2258-2270.
6. Michie, A. M., R. Nakagawa, and A. M. McCaig. 2007. Murine models for chronic lymphocytic leukaemia. Biochem. Soc. Trans. 35: 1009-1012. (Pubitemid 350206415)
7. Fuchs, B., and A. Braun. 2008. Improved mouse models of allergy and allergic asthma: chances beyond ovalbumin. Curr. Drug Targets 9: 495-502. (Pubitemid 352025206)
8. Giarratana, N., G. Penna, and L. Adorini. 2007. Animal models of spontaneous autoimmune disease: type 1 diabetes in the nonobese diabetic mouse. Methods Mol. Biol. 380: 285-311. (Pubitemid 350183335)
9. Braun, A., A. Rigotti, and B. L. Trigatti. 2008. Myocardial infarction following atherosclerosis in murine models. Curr. Drug Targets 9: 217-223. (Pubitemid 351843603)
10. Barth, H., E. Robinet, T. J. Liang, and T. F. Baumert. 2008. Mouse models for the study of HCV infection and virus-host interactions. J. Hepatol. 49: 134-142.
11. Mizgerd, J. P., and S. J. Skerrett. 2008. Animal models of human pneumonia. Am. J. Physiol. 294: L387-L398.
12. Chesselet, M. F., S. Fleming, F. Mortazavi, and B. Meurers. 2008. Strengths and limitations of genetic mouse models of Parkinson's disease. Parkinsonism Relat. Disord. 14(Suppl. 2): S84-S87.
13. Torres-Aleman, I. 2008. Mouse models of Alzheimer's dementia: current concepts and new trends. Endocrinology 149: 5952-5957.
14. Reddy, P., Negrin, R., and Hill, G. R. 2008. Mouse models of bone marrow tansplantation. Biol. Blood Marrow Transplant. 14: 129-135. (Pubitemid 350286851)
15. Bishop, M. R. 2004. Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer. Haematologica 89: 599-605. (Pubitemid 38691248)
16. Bishop, M. R., D. H. Fowler, D. Marchigiani, K. Castro, C. Kasten-Sportes, S. M. Steinberg, J. C. Gea-Banacloche, R. Dean, C. K. Chow, C. Carter, et al. 2004. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J. Clin. Oncol. 22: 3886-3892.
17. Lundqvist, A., and R. Childs. 2005. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J. Immunother. 28: 281-288. (Pubitemid 40962319)
18. Korngold, R., and J. Sprent. 1978. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice: prevention by removing mature T cells from marrow. J. Exp. Med. 148: 1687-1698.
19. Korngold, R., and J. Sprent. 1981. H-2 restriction of T cells causing lethal graft-versus-host disease across minor histocompatibility barriers in mice. Transplant. Proc. 13: 1217-1219.
20. + T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J. Exp. Med. 165: 1552-1564.
21. Hamilton, B. L., M. J. Bevan, and R. Parkman. 1981. Anti-recipient cytotoxic T lymphocyte precursors are present in the spleens of mice with acute graft versus host disease due to minor histocompatibility antigens. J. Immunol. 126: 621-625.
22. Martin, P. J., J. A. Hansen, B. Torok-Storb, L. Moretti, O. Press, R. Storb, E. D. Thomas, P. L. Weiden, and E. S. Vitetta. 1988. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplant. 3: 437-444.
23. Nash, R. A., and R. Storb. 1996. Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL. Curr. Opin. Immunol. 8: 674-680.
24. Korngold, R., C. Leighton, and T. Manser. 1994. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58: 278-287.
25. Fontaine, P., G. Roy-Proulx, L. Knafo, C. Baron, D. C. Roy, and C. Perreault. 2001. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat. Med. 7: 789-794. (Pubitemid 32691632)
26. Bleakley, M., and S. R. Riddell. 2004. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 4: 371-380.
27. Weiden, P. L., N. Flournoy, E. D. Thomas, R. Prentice, A. Fefer, C. D. Buckner, and R. Storb. 1979. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300: 1068-1073.
28. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ringden, C. Rozman, B. Speck, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75: 555-562.
29. Collins, R. H., Jr., O. Shpilberg, W. R. Drobyski, D. L. Porter, S. Giralt, R. Champlin, S. A. Goodman, S. N. Wolff, W. Hu, C. Verfaillie, et al. 1997. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15: 433-444.
30. Kolb, H. J., A. Schattenberg, J. M. Goldman, B. Hertenstein, N. Jacobsen, W. Arcese, P. Ljungman, A. Ferrant, L. Verdonck, D. Niederwieser, et al. 1995. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86: 2041-2050.
31. Slavin, S., S. Morecki, L. Weiss, and R. Or. 2002. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J. Hematother. Stem Cell Res. 11: 265-276.
32. Falkenburg, J. H., L. van de Corput, E. W. Marijt, and R. Willemze. 2003. Minor histocompatibility antigens in human stem cell transplantation. Exp. Hematol. 31: 743-751.
33. Roopenian, D., E. Y. Choi, and A. Brown. 2002. The immunogenomics of minor histocompatibility antigens. Immunol. Rev. 190: 86-94.
34. Mendoza, L. M., P. Paz, A. Zuberi, G. Christianson, D. Roopenian, and N. Shastri. 1997. Minors held by majors: the H13 minor histocompatibility locus defined as a peptide/MHC class I complex. Immunity 7: 461-472.
35. Zuberi, A. R., G. J. Christianson, L. M. Mendoza, N. Shastri, and D. C. Roopenian. 1998. Positional cloning and molecular characterization of an immunodominant cytotoxic determinant of the mouse H3 minor histocompatibility complex. Immunity 9: 687-698.
36. Perreault, C., J. Jutras, D. C. Roy, J. G. Filep, and S. Brochu. 1996. Identification of an immunodominant mouse minor histocompatibility antigen (MiHA): T cell response to a single dominant MiHA causes graft-versus-host disease. J. Clin. Invest. 98: 622-628.
37. Mendoza, L. M., G. Villaflor, P. Eden, D. Roopenian, and N. Shastri. 2001. Distinguishing self from nonself: immunogenicity of the murine H47 locus is determined by a single amino acid substitution in an unusual peptide. J. Immunol. 166: 4438-4445.
38. Greenfield, A., D. Scott, D. Pennisi, I. Ehrmann, P. Ellis, L. Cooper, E. Simpson, and P. Koopman. 1996. An H-YDb epitope is encoded by a novel mouse Y chromosome gene. Nat. Genet. 14: 474-478.
39. Murata, M., E. H. Warren, and S. R. Riddell. 2003. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J. Exp. Med. 197: 1279-1289.
40. Malarkannan, S., P. P. Shih, P. A. Eden, T. Horng, A. R. Zuberi, G. Christianson, D. Roopenian, and N. Shastri. 1998. The molecular and functional characterization of a dominant minor H antigen, H60. J. Immunol. 161: 3501-3509.
41. Malarkannan, S., T. Horng, P. Eden, F. Gonzalez, P. Shih, N. Brouwenstijn, H. Klinge, G. Christianson, D. Roopenian, and N. Shastri. 2000. Differences that matter: major cytotoxic T cell-stimulating minor histocompatibility antigens. Immunity 13: 333-344.
42. Brickner, A. G., E. H. Warren, J. A. Caldwell, Y. Akatsuka, T. N. Golovina, A. L. Zarling, J. Shabanowitz, L. C. Eisenlohr, D. F. Hunt, V. H. Engelhard, and S. R. Riddell. 2001. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J. Exp. Med. 193: 195-206.
43. Yadav, R., Y. Yoshimura, A. Boesteanu, G. J. Christianson, W. U. Ajayi, R. Shashidharamurthy, A. K. Stanic, D. C. Roopenian, and S. Joyce. 2003. The H4b minor histocompatibility antigen is caused by a combination of genetically determined and posttranslational modifications. J. Immunol. 170: 5133-5142.
44. Wettstein, P. J. 1986. Immunodominance in the T-cell response to multiple non-H-2 histocompatibility antigens, II: Observation of a hierarchy among dominant antigens. Immunogenetics 24: 24-31.
45. Korngold, R., and P. J. Wettstein. 1990. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens. J. Immunol. 145: 4079-4088.
46. Berger, M., P. J. Wettstein, and R. Korngold. 1994. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 57: 1095-1102.
47. Korngold, R. 1993. Biology of graft-vs.-host disease. Am. J. Pediatr. Hematol. Oncol. 15: 18-27.
48. Zilberberg, J., D. McElhaugh, L. N. Gichuru, R. Korngold, and T. M. Friedman. 2008. Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vβ spectratype analysis. J. Immunol. 180: 5352-5359.
49. + T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens. Biol. Blood Marrow Transplant. 10: 224-235.
50. Lai, L., N. Alaverdi, L. Maltais, and H. C. Morse III. 1998. Mouse cell surface antigens: nomenclature and immunophenotyping. J. Immunol. 160: 3861-3868.
51. Taft, R. A., M. Davisson, and M. V. Wiles. 2006. Know thy mouse. Trends Genet. 22: 649-653.
52. Bailey, D. W. 1982. How pure are inbred strains of mice? Immunol. Today 3: 210-214.
53. Specht, C. G., and R. Schoepfer. 2001. Deletion of the α-synuclein locus in a subpopulation of C57BL/6J inbred mice. BMC Neurosci. 2: 11.
54. Vance, R. E., A. M. Jamieson, D. Cado, and D. H. Raulet. 2002. Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. Proc. Natl. Acad. Sci. USA 99: 868-873.
55. Watkins-Chow, D. E., and W. J. Pavan. 2008. Genomic copy number and expression variation within the C57BL/6J inbred mouse strain. Genome Res. 18: 60-66.
56. + T cell responses to minor histocompatibility antigens involved in graft-versus-host disease. J. Immunol. 161: 41-48.
57. Korngold, R., C. Leighton, L. E. Mobraaten, and M. A. Berger. 1997. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens. Biol. Blood Marrow Transplant. 3: 57-64.
58. Blazar, B. R., D. C. Roopenian, P. A. Taylor, G. J. Christianson, A. Panoskaltsis-Mortari, and D. A. Vallera. 1996. Lack of GVHD across classical, single minor histocompatibiliTy (miH) locus barriers in mice. Transplantation 61: 619-624.
59. Jones, S. C., T. M. Friedman, G. F. Murphy, and R. Korngold. 2004. Specific donor Vβ-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens. Biol. Blood Marrow Transplant. 10: 91-105.
60. Alpdogan, O., C. Schmaltz, S. J. Muriglan, B. J. Kappel, M.-A. Perales, J. A. Rotolo, J. A. Halm, B. E. Rich, and M. R. M. van den Brink. 2001. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood 98: 2256-2265.
61. Mackall, C. L., F. T. Hakim, and R. E. Gress. 1997. T-cell regeneration: all repertoires are not created equal. Immunol. Today 18: 245-251.
62. Wang, L., L. Yang, M. D. Filippi, D. A. Williams, and Y. Zheng. 2006. Genetic deletion of Cdc42GAP reveals a role of Cdc42 in erythropoiesis and hematopoietic stem/progenitor cell survival, adhesion, and engraftment. Blood 107: 98-105.
63. Gu, Y., J. E. Siefring, L. Wang, H. D. Chae, J. R. Bailey, and Y. Zheng. 2006. Oncogenic Vav1 induces Rac-dependent apoptosis via inhibition of Bcl-2 family proteins and collaborates with p53 deficiency to promote hematopoietic progenitor cell proliferation. Oncogene 25: 3963-3972.
64. Scheller, M., J. Huelsken, F. Rosenbauer, M. M. Taketo, W. Birchmeier, D. G. Tenen, and A. Leutz. 2006. Hematopoietic stem cell and multilineage defects generated by constitutive β-catenin activation. Nat. Immunol. 7: 1037-1047.
65. Kirstetter, P., K. Anderson, B. T. Porse, S. E. Jacobsen, and C. Nerlov. 2006. Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. Nat Immunol. 7: 1048-1056.
66. Gilliland, D. G., and J. D. Griffin. 2002. The roles of FLT3 in hematopoiesis and leukemia. Blood 100: 1532-1542.
67. Levis, M., and D. Small. 2003. FLT3: ITDoes matter in leukemia. Leukemia 17: 1738-1752.
68. McKenna, H. J., K. L. Stocking, R. E. Miller, K. Brasel, T. De Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B. Pulendran, et al. 2000. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95: 3489-3497.